Clinsight is dedicated to transforming the landscape of prostate cancer diagnosis and treatment. We believe that every patient deserves an expert pathologist and a precise prognosis, regardless of where they live.
Prostate cancer affects millions of men worldwide, with 1.4 million new diagnoses annually. Yet, current diagnostic methods leave 30% of lethal cases undetected early on and misgrade 40% of patients. We are here to change that with ClinAI™.
To provide outcome-based risk prediction and precise grading for every prostate cancer patient, eliminating unnecessary treatments and ensuring life-saving interventions are delivered when they matter most.
Built on over 15 years of exclusive research data and powered by world-leading AI, Clinsight is obtaining EU regulatory approval to bring this life-saving technology to market. With a team of renowned scientists, clinicians, and experienced entrepreneurs, we are poised to set a new standard in digital pathology.